Xcout IntelNuevocor competitors & alternatives
The 12 closest competitors and alternatives to Nuevocor among biotech companies — ranked by similarity to what Nuevocor actually does, not by market-cap band.
Subscribe to see Nuevocor’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Nuevocor
Nuevocor is a biotechnology research company with its headquarters located in Singapore and additional operations in the United States and France. The company focuses on developing breakthrough gene therapies to treat untreatable cardiomyopathies.
Nuevocor at a glance
Nuevocor is a biotech company headquartered in Singapore. It has raised at least $45M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series B, raised $45M in May 2025. Xcout tracks 17 named people at Nuevocor, including Albert Gianchetti (Chief Executive Officer).
Nuevocor leadership
- Albert GianchettiChief Executive Officer
- Monica ShahChief Medical Officer
- Nicolas Guyon-GellinChief Business Officer
- Andreas WallnoeferBoard Chairman
- Brian BurkeCo-Founder and Advisor
- Colin StewartCo-Founder and Advisor
11 more named people on record for Nuevocor, with roles, board committees and tenure — see the full roster →
Nuevocor funding rounds
At least $45M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $45M | 5 named | |
| — | Undisclosed | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Nuevocor competitors
Ranked by semantic similarity — how close each company is to Nuevocor by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Biotechnology
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Biotechnology
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Similar biotech company
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Similar biotech company
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Biotechnology
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Biotechnology
Myosana Therapeutics, Inc. is a biotechnology research company based in Seattle, Washington, pioneering non-viral gene therapy treatments for muscle diseases.
Biotechnology
Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.
Biotechnology
Hunterian Medicine LLC is a gene-editing company that develops CRISPR-based therapeutics to cure genetic diseases. The company utilizes a patented platform technology with a bidirectional promoter to enable efficient, on-target delivery of CRISPR via a single adeno-associated virus (AAV).
Similar biotech company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Biotechnology
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotech company
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Nuevocor and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Nuevocorand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →